Del Sette Capital Management LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Del Sette Capital Management bought 2,919 shares of Regeneron (≈$2.25M) in Q4, making up about 1.4% of its portfolio and its 25th-largest holding.
• Regeneron beat Q1 estimates (EPS $9.47 vs. $8.91; revenue $3.61B, +19% YoY) and announced a $3 billion share buyback, but shares fell on mixed investor reaction.
• The company declared a quarterly dividend of $0.94 (annual $3.76, yield ~0.5%); analyst views are mixed (Guggenheim raised its target to $995, consensus ~$826.59) while insiders sold ~3,774 shares (~$2.94M) last quarter.

Del Sette Capital Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,919 shares of the biopharmaceutical company's stock, valued at approximately $2,253,000. Regeneron Pharmaceuticals makes up approximately 1.4% of Del Sette Capital Management LLC's investment portfolio, making the stock its 25th biggest position.

A number of other large investors have also added to or reduced their stakes in REGN. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 25 shares in the last quarter. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $27,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. Caitlin John LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $34,000. Finally, FNY Investment Advisers LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $38,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $701.42 on Friday. The business's 50 day moving average price is $756.81 and its 200 day moving average price is $735.17. The firm has a market cap of $74.15 billion, a P/E ratio of 17.09, a P/E/G ratio of 1.63 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals's revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.22 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,774 shares of company stock worth $2,942,738 over the last quarter. Insiders own 7.02% of the company's stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a report on Thursday. Cantor Fitzgerald restated an "overweight" rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Oppenheimer restated an "outperform" rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $826.59.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.